Search
Myomo Inc
MYOAdd to Watchlist
1.030USD
0.0000.00%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
39.72MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
0.00%
5 Days
0.00%
1 Month
-20.16%
6 Months
+4.04%
Year to Date
+13.19%
1 Year
-49.26%
Key Figures
1.060Open
1.095High
399.07KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
1.03%Turnover Ratio
1.040Prev. Close
1.010Low
250.69KTurnover
LossP/E Static
4.41P/B
0.00%Div Yield TTM
-38.95%ROA
3.13952wk High
0.42Volume Ratio
-6.18MNet Profit
38.57MShares
-0.3597EPS TTM
1.45Beta
-98.53%ROE
0.60552wk Low
8.17%Amplitude
68.24%Gross Margin
39.72MMarket Cap
-3.61Reward/Risk
5.36%Risk Rate
TradingKey Stock Score of Myomo Inc
Currency: USD Updated: 2026-07-02Key Insights
Myomo Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 113 out of 204 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 4.42.In the medium term, the stock price is expected to trend up.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Myomo Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Myomo Inc Highlights
StrengthsRisks
Myomo, Inc. is a wearable medical robotics company that offers improved arm and hand function for those suffering from neurological disorders and upper-limb paralysis. The Company develops and markets the MyoPro product line, which is a myoelectric-controlled upper limb brace, or orthosis. MyoPro is a powered upper-limb orthosis designed to support the arm and restore function to the weakened or paralyzed arms of certain patients suffering from CVA stroke, brachial plexus injury, traumatic brain or spinal cord injury or other neuromuscular disease or injury. MyoPro senses a patient’s own electromyography (EMG) signals through non-invasive sensors on the arm and can restore an individual’s ability to perform activities of daily living, including feeding themselves, carrying objects and doing household tasks. MyoPro’s control technology utilizes an advanced human-machine interface based on non-invasive, patented electromyography, or EMG, control technology.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 112.71% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 40.93M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 40.93M.
Overvalued
The company’s latest PE is -2.86, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 23.44M shares, decreasing 19.96% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 15.93K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 1.10.
Analyst Rating
Based on
5
analysts
Buy
Current Rating
4.420
Target Price
+325.00%
Upside Space
Myomo Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Myomo Inc Info
Myomo, Inc. is a wearable medical robotics company that offers improved arm and hand function for those suffering from neurological disorders and upper-limb paralysis. The Company develops and markets the MyoPro product line, which is a myoelectric-controlled upper limb brace, or orthosis. MyoPro is a powered upper-limb orthosis designed to support the arm and restore function to the weakened or paralyzed arms of certain patients suffering from CVA stroke, brachial plexus injury, traumatic brain or spinal cord injury or other neuromuscular disease or injury. MyoPro senses a patient’s own electromyography (EMG) signals through non-invasive sensors on the arm and can restore an individual’s ability to perform activities of daily living, including feeding themselves, carrying objects and doing household tasks. MyoPro’s control technology utilizes an advanced human-machine interface based on non-invasive, patented electromyography, or EMG, control technology.
Ticker SymbolMYO
CompanyMyomo Inc
CEOGudonis (Paul R)
Websitehttps://myomo.com/
Related Instruments
-0.37%
+1.91%
+3.48%
+5.87%
+2.10%
-0.10%
+4.19%
+5.03%
+4.30%
+0.25%
+3.65%
+4.74%
+2.79%
+2.59%
-3.06%
+3.40%
+3.76%
+1.10%
+0.28%
-2.09%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Myomo Inc (MYO)?
The current price of Myomo Inc (MYO) is 1.03.
What is the symbol of Myomo Inc?
The ticker symbol of Myomo Inc is MYO.
What is the 52-week high of Myomo Inc?
The 52-week high of Myomo Inc is 3.14.
What is the 52-week low of Myomo Inc?
The 52-week low of Myomo Inc is 0.60.
What is the market capitalization of Myomo Inc?
The market capitalization of Myomo Inc is 39.72M.
Is Myomo Inc (MYO) currently rated as Buy, Hold, or Sell?
According to analysts, Myomo Inc (MYO) has an overall rating of Buy, with a price target of 4.42.
What is the Earnings Per Share (EPS TTM) of Myomo Inc (MYO)?
The Earnings Per Share (EPS TTM) of Myomo Inc (MYO) is -0.37.